E. Garrett Ingram is a top biotech executive with intimate expertise in global medicines and market access. Garrett brings more than twenty years of experience in pharmaceuticals, biotech, and device marketing. She has a proven track record of distinguished leadership, guiding organizations through turnarounds and delivering profitability in the top and bottom-line growth. In July 2020, Garrett was appointed President; CEO of Cipla Therapeutics, Inc. leading the institutional specialty business.
Prior to her role at Cipla, Ms. Ingram served as Chief Marketing Officer at MannKind Corporation, Senior Vice President, Managed Markets at Dexcom and Vice President, Head of Market Access at Sanofi, and Vice President of Market Access Strategy at Bristol Myers Squibb (BMS).
Garrett holds a Bachelor of Science degree from East Carolina University and a master’s degree in public health and community education from the University of South Carolina. She has also
completed executive leadership programs in pharmaceuticals and leadership at The Wharton School of Business and dedicates her free time to mentorship and making a community impact.
Currently, she is a board member of Avenue Therapeutics Inc., serves on the audit committee, and is a board member of Cipla Therapeutics, Inc.
Prior to her role at Cipla, Ms. Ingram served as Chief Marketing Officer at MannKind Corporation, Senior Vice President, Managed Markets at Dexcom and Vice President, Head of Market Access at Sanofi, and Vice President of Market Access Strategy at Bristol Myers Squibb (BMS).
Garrett holds a Bachelor of Science degree from East Carolina University and a master’s degree in public health and community education from the University of South Carolina. She has also
completed executive leadership programs in pharmaceuticals and leadership at The Wharton School of Business and dedicates her free time to mentorship and making a community impact.
Currently, she is a board member of Avenue Therapeutics Inc., serves on the audit committee, and is a board member of Cipla Therapeutics, Inc.
Activity